MCB529 2-27-13: Circadian Control of Liver Function
Sep 5, 2023
What's Missouri's name?
Northeast.
That's Roman's name in Missouri.
And then she came here for a PhD in physiology.
And she worked on reproductive system in chickens.
I was reminded of that today with Janice Barr.
And then she came over and did a post-doc in our lab
on the neuro basis of circadian rhythms.
And then she took a position in comparative biosciences here
and started out on a career of her own.
And she sort of established and discovered
the field she's going to be talking to you about today.
She's now associate professor and mover and shaker
over the pharmacology department at UIS Medical
School in Springfield.
And she just agreed to come over and tell us
what she's been up to.
So I'm always more excited than me
to hear what she's going to tell us.
So welcome, Shelly.
So thanks to Martha for inviting me over
to talk to your class today.
So what I'd like to start out by saying
is that this really is a very new area,
I think, in the circadian rhythms field, even,
to look at the interaction.
What we're going to look at today
is a lot of interaction between the circadian rhythm,
the circadian timing system, and the system that
is in place for detoxifying chemicals or things
that you might take in that are out in the environment,
pesticides, things that you might eat in your diet
that aren't easily digestible, things like that.
But we're going to look today at how these two systems interact
and how this interaction of these two systems,
if it doesn't work properly, can lead to disease states.
So we'll start here.
And I'm going to assume that you know a lot of the basics.
And Martha said she gave six lectures.
So you guys should be up to speed on circadian rhythms.
But if there's anything that you don't understand
as I'm going through, please just raise your hand
or just jump in and ask a question.
And I'm happy to have a discussion with you about it.
So this may be a little bit different clock
diagram than what you guys are used to seeing,
because I'm sure that most of us, when we talk about rhythms,
we put the SCN, the suprachiasmatic nucleus,
up there at the top.
And everything else is just kind of down here at the bottom.
But today, what we're really going to be focused on
is things that are really happening
and going on in the liver.
And so most of my talk really is about things
that are happening in the liver.
But more than that, it's about how
the clock in the liver interacts with the clock in the brain.
So most of you, you should know by now
that there is a central clock located
in the suprachiasmatic nucleus.
It's the master clock.
It drives the rhythms in the rest of the body.
And then we have a clock down here in the liver.
And this clock in the liver, the clock genes
are present in the liver.
They oscillate with 24-hour periodicity.
But typically, the clock in the liver
is driven by either the clock in the brain, the SCN,
or by food.
So there are two different ways that the clock in the liver
can be regulated, either by the SCN or by feeding.
But what I want to focus on is the liver clock itself,
for just a minute, and the liver itself.
The other aspect of what we're going to talk about today
is not just clocks, but it's about toxicity.
And one of the major functions of the liver
is to metabolize chemicals, metabolize drugs
that you might be taking, metabolize
any sorts of chemicals that are in your body, metabolism
of hormones, all sorts of things,
are broken down in the liver.
So this is a basic diagram that shows how things
are broken down in the liver.
And what I'm going to really focus on in my talk today
are these things called fat-soluble toxins that
might be in the environment.
These might be pesticides that are sprayed on farm crops that
get into your food.
These might be formed from pollution,
so in the process of paper, bleaching, or garbage burning,
or any other sorts of smokestack that you might see
is going to put out chemicals into the environment.
And some of those chemicals that are
found in the smoke that comes out of there
are fat-soluble toxins.
And they can get into your body.
And once they get into your body,
they make their way to the liver.
And they're broken down, typically, in two steps.
The first is the production.
After these toxins get in the liver,
it causes the production of cytochrome P450 enzymes.
And these cytochrome P450 enzymes act on the toxins.
And what they typically do is they
will do one of these five things, oxidation, reduction,
hydrolysis, hydration, or dehalogenation.
So basically, the cytochrome P450 enzymes
latch onto these chemicals that come into the body.
And they break them down.
And what they do is after they act,
these phase one P450 enzymes, they work on the toxins.
And they form an intermediate metabolite.
So the chemical comes in.
It's a certain structure.
The P450 enzyme comes in, adds an oxidative group onto it,
or causes hydrolysis.
And it forms an intermediate metabolite.
These intermediate metabolites are sometimes way more toxic
than the original compound.
And so they can be big problems.
But typically, what happens is the intermediate metabolite
is then acted on by another set of enzymes in the liver that
will conjugate it.
So they put a sulfate group or a glucuronidate group
onto this chemical.
And basically, what this does is it makes it water soluble.
And it makes it so we go from a fat soluble through two steps.
And we end up with a water soluble compound
that then is gotten rid of and excreted
either in the gallbladder, through the gallbladder,
and or the kidneys.
So I want to talk a little bit more
about one class of these fat soluble toxins.
And they are classified as dioxin.
So dioxin is probably the most dangerous, the most toxic
chemical known to man.
So I'm going to show you some structures of dioxins
in a couple slides.
So how do you get exposed to dioxin?
Dioxin exposure can occur by accident.
Agent Orange, which was present in Vietnam,
was filled with chemicals called dioxins.
And there was a big spill in Italy in 1976
where dioxins were just spewed into the environment.
So people were exposed to very high levels of dioxins.
But more commonly, people and animals
are exposed to dioxins in the environment
because they can be produced as byproducts
of these different types of processes.
So any time there's incineration going on
to get rid of waste products in the environment,
dioxins will be given off as a product of that
into the smoke and into the atmosphere.
Many pesticides, and in the production of pesticides
or the pesticides themselves and PVC's production of those,
the process of chlorine bleaching
can leach out or cause dioxins to be produced.
And one of the more common ones is the production of paper.
So when they make paper and they bleach paper to be produced,
dioxins are given off as a byproduct of this.
And one thing that I don't have up here that's more recent
and is in your microwave.
So some of the plastic things that you store food in,
you put those in the microwave,
the plastics will leach dioxins into the food.
So there's all sorts of different places
where you can be exposed to dioxins.
So why is this bad?
So we're gonna talk a little bit about why this is bad.
Well, what happens if you have too much dioxin?
Well, here's all, this is a list of the things that can go wrong
if you get exposed to high levels or dioxins build up in your body.
And I should say before I go on,
is these chemicals, once they're produced, the dioxins,
they get into your body and they're not easily broken down
by that liver metabolism.
The liver metabolism doesn't work very well on them,
especially that second phase of liver metabolism.
So what you end up with is in your body,
either the parent dioxin compound
or that reactive intermediate,
and they build up and they're fat-soluble.
So they get stored in fat or in places where...
in the liver or in fat, and so they build up.
And it's estimated that the half-life for dioxins
in the human body is ten years.
So it's not something that's easy to get rid of, OK?
So they can...
So I guess my point is,
you don't have to have one single high-level exposure
to dioxin for it to cause a problem.
But what more likely occurs in human beings
is that you get low levels of dioxin
and you're exposed to low levels of dioxin
over the course of years,
and it builds up and builds up and builds up,
and then causes a problem after it reaches a certain level.
And these are the kinds of problems that you can get.
You can see everything from cancer
to neuronal deficits and decreased IQ.
There's a professor out at Vet Med
who actually studies the effects of PCBs and dioxins
on IQ and learning and memory in children.
And so she works in that area.
But one of the things that I like to high...
I'm gonna highlight today in my talk
is that dioxin toxicity can lead to diabetes
and changes in metabolism and ultimately diabetes,
and it can lead to sleep disturbances.
And I got really interested in this research area
because when I had my faculty position here,
there was this old guy that was a toxicologist,
and he came up to me one day and he said,
Shelley, you know, in the 70s,
I worked with a group of people
who were exposed to really high levels of dioxins,
and they kept telling me that they couldn't sleep.
And well, being a good circadian rhythms biologist
that I was, I said, huh, they can't sleep.
Well, I wonder if that has something to do
with their circadian timing system
because sleep and circadian rhythms are intertwined.
So I started to look into that,
and that's a lot of what I'm gonna tell you today
is the result of looking into that process.
So dioxins binds to a receptor
called the aryl hydrocarbon receptor
or the dioxin receptor.
So when they come into the body,
they're lipophilic, they accumulate in fat,
they make it into the liver,
they make it lots of different places,
and when they get into a cell,
they're gonna bind to this protein
called the aryl hydrocarbon receptor.
And I will tell you right now
as we go on to the next few slides
that this aryl hydrocarbon receptor
is the link between dioxins and the circadian clock.
And I'll tell you why in just a little bit.
It's just a little bit more about some of these chemicals
that will bind to the dioxin receptor.
So the dioxin receptor is in the body,
it's almost ubiquitously expressed.
It's expressed all throughout the body,
in the brain, liver, high levels in the gut,
in the skin, lots of different places.
But it's been classified for a long time
as an orphan receptor,
meaning nobody really knows what its endogenous ligand is.
But it's been studied for the last 50 years
for its binding of these chemicals
in the environment and in toxicology.
So what kinds of things binds to this receptor?
Well, I'll tell you, this receptor itself
is not very specific.
It binds to classes of compounds,
not just one specific thing.
So you think of the estrogen receptor, for example.
It binds really highly to estrogen,
and it doesn't really like to bind to anything else.
This receptor's not like that.
It binds to lots and lots of different things.
And it's very ancient.
It's really been there for a really long time
throughout evolution.
And its role, one of its major roles,
is when an animal or a person takes in
and gets something inside their system that's toxic,
they wanna get rid of it, right?
So the goal of this receptor is to get rid of those things.
So, or one of its functions.
So what kinds of things bind to the dioxin receptor?
Well, this group of chemicals
called halogenated aromatic hydrocarbons.
This one, TCDD, you should remember that one.
There's the structure of it over there.
That's the one that's really, really, really, really toxic.
That's the thing that's in the dioxins
that is really, really detrimental to people.
But other things like this one, benzo-A-pyrene,
is a component of cigarette smoke.
So that one will bind to the aryl hydrocarbon receptor.
And more recently, what we know
is that there are things in your diet,
like flavonoids, genistein, which is a flavonoid,
it can bind to the aryl hydrocarbon receptor.
And of course, for the last 34 years,
everybody's been looking for, asking the question,
what's the endogenous receptor for this?
Is there an endogenous receptor for this?
That's like the $50 million question in this area.
And what we know is, and one of the reasons
that we got interested in this was because,
if you look at this first thing
that's known as an endogenous ligand,
what you see here is it's a tryptophan photoproduct.
Well, if you know anything about circadian rhythms,
we know that light is the major entraining factor
for the circadian timing system.
So when light hits the body, it does all sorts of things
other than just cause regulation of your circadian rhythm.
And one of the things that light can do within the skin
is the conversion of tryptophan
into this compound over here called FICZ.
And this FICZ has really, really, really high affinity
for the aryl hydrocarbon receptor.
So one of the questions that I'm gonna get back to
is we asked was, does light cause the production of FICZ,
which can bind to the aryl hydrocarbon receptor
and regulate your circadian rhythm,
interact with your circadian rhythm?
But I'll get back to that in a minute.
For now, I want you to get an appreciation
that there's lots of different kinds of compounds
that can bind to this particular receptor.
All right, so how does it work?
So we're focusing still on aryl hydrocarbon receptor
and the toxicology now.
But the aryl hydrocarbon receptor
is a cytoplasmic receptor.
When it's not bound to any ligand,
it sits in the cytoplasm,
and it's bound to HSP, a heat shock protein,
and there's a couple other proteins that bind to it
and make it stay in the cytoplasm.
So then when some chemical comes and binds to the AHR,
it will then move into the nucleus.
And once it moves into the nucleus,
it will form a heterodimer with another compound called ARNT.
And what I want you to start to think about
as I'm telling you this,
is that these AHR and ARNT
are very similar to CLOCK and BMAL.
Okay, they bind together in the same way
that CLOCK and BMAL bind.
In fact, BMAL is brain muscle ARNT-like protein
because it's a homolog of this particular protein.
Okay, so they're very similar.
So AHR binds to its ligand, it moves into the nucleus,
forms a heterodimer with ARNT,
and then once they form this heterodimer,
just like CLOCK and BMAL sit down on the E-boxes
in the CLOCK gene or in the CLOCK and DRIVE transcription,
AHR and ARNT binds to xenobionic response elements, XREs,
or dioxin response elements
in the promoters of certain genes.
And some of the genes that they bind to
in the liver in particular, or DRIVE in the liver,
are these P450 enzymes.
Okay, so you can think of this as a way,
this nasty chemical gets into the cell,
it activates aryl hydrocarbon receptor,
DRIVE's transcription of P450 enzymes,
the P450 enzymes should then come back
and metabolize or break down the ligand.
So that's the whole idea,
is that the ligand basically is self-destruction, right?
So the ligand binds AHR,
AHR sets into motion this series of events,
and it comes back and breaks down the protein,
the chemical.
Two of the most important P450 enzymes
that are target genes for the AHR ARNT
are CYP1A1 and CYP1B1.
I want you to hold onto those
because I'm gonna talk about those
when I talk about how there's an interaction
with CLOCK and AHR.
So if we look at the structure of the AHR,
the aryl hydrocarbon receptor,
as I said before, it's very much like CLOCK and BMAL.
So if you look at the structure of the receptor,
you see that the AHR has two PAS domains,
PAS A and PAS B,
which are protein-protein interaction domains.
Just, and look, this just shows you the similarity
between the structure of AHR and the structure of CLOCK.
So they're very, very similar proteins.
They're PAS domain, it's a PAS domain containing protein,
they're members of the same family of genes.
What's really kind of interesting
about the PAS domain family
is you can divide the PAS domain proteins into two groups.
They can call them the alpha class and the beta class.
Basically, the alpha class, you can think of as sensors,
environmental sensors or sensors,
like HIF1-alpha is a sensor for hypoxia.
CLOCK is a sensor for, maybe for NAD and things like that.
But these guys are sensors.
And then the beta class are binding partners
that help direct, once one of these guys
binds with one of those guys over there,
those, the beta class directs them
to a specific place on the gene,
in specific genes to drive transcription.
But what we know is that R3 over there
is the same as BMAL.
So this class, the alpha class over here
can form partners with beta class members,
but they can form, it's not a one-to-one relationship.
It's not like CLOCK always binds to BMAL.
For example, ART can bind to HIF1-alpha or AHR or CYM1.
ART2 can bind to all of these guys.
And BMAL1, of course we know that it binds to CLOCK
and it can bind to HIF1-alpha, it can bind to NPAS2.
So they form all sorts of different combinations
and the different combinations determine where they go
and which genes they turn on, okay?
So what we asked was because these guys
are in the same family of proteins,
is can the AHR binds to BMAL?
Because remember, AHR normally binds to ART.
And BMAL and ART are very, very similar proteins.
So we asked that question, do they bind together?
Because if they bind together,
then they could have a potential for regulating the CLOCK,
regulating the circadian clock.
And so we did a pulldown and this is what we found.
So this is, basically we did a chromatin,
or sorry, we did a COIP, an immunoprecipitation.
So we took our animals and we treated them
either as control or we treated them
with an agonist of the aryl hydrocarbon receptor.
And what we see is that, and then we pulled down
with an antibody against the AHR and probed for BMAL.
So what this is gonna tell us
is the two of them are sticking together.
Okay, as we can see that when we pull down
with an antibody for AHR,
so everything that bound to AHR comes down
and then we run it all in a gel
and we see that it binds to BMAL.
So these two can interact with each other,
which tells us that it has a potential
to be interacting with the CLOCK,
interacting with circadian rhythms.
And so I'm not gonna spend a lot of time on this.
This is just the regular CLOCK that you've seen before.
So we have CLOCK and BMAL.
So what we're gonna hypothesize when we do our studies
is that AHR can interfere with this CLOCK and BMAL binding.
So AHR can pull these two apart
and AHR can interrupt this and interrupt the CLOCK.
Can I ask questions here?
Yes, please do.
So on the previous slide,
do you think that it binds in the same spot as CLOCK
or do you think it binds in more like an allosteric site?
No, they bind through their past domains.
So they bind, I don't know if it's exactly the same,
but it's through that particular motif
that they bind.
So it could be slightly different,
but it's that structural arrangement that binds.
Okay.
All right, let's skip.
All right.
So what I wanna spend the rest of the time talking about
is this interrelationship.
First, we're gonna ask the question,
does the CLOCK alter aryl hydrocarbon receptor
or dioxin signaling?
And then we're gonna come back
and ask the opposite question.
Does dioxin signaling affect the CLOCK?
And what, we don't know a lot about this area.
This is a very new and emerging area of research.
And what we know, what we do know
is that there does seem to be this reciprocal relationship.
AHR signaling affects circadian rhythms
and circadian rhythms affect the ability
of the AHR to metabolize dioxins, okay?
So there's, so the first question we're gonna look at
is does the CLOCK interfere
or does the CLOCK direct dioxin signaling or AHR signaling?
So I'm gonna tell you the answer is yes.
And this is sort of the take-home message
of the next several slides.
AHR signaling is regulated by the CLOCK.
So that's big, big take-home message.
So this is some, a study that we did in my lab.
And we did this in mice.
And basically what we did was we looked at the expression
of aryl hydrocarbon receptor,
two CLOCK genes, PIR1 and BMAL, and CYP1A1.
Remember, that's the target gene for AHR.
So what we found is that in both the SCN and the liver,
and you can see there's a,
and so the solid lines are from animals
that were in a light-dark cycle.
And the dotted lines are for animals kept in DD.
And you should probably all know by now
that when you put them in DD,
that tells you that it's regulated
by the endogenous CLOCK, right?
So we can see that both PIR1 and BMAL1,
so nice circadian rhythms, both in LD and DD,
in both the SCN and the liver, like you would expect.
And then we did AHR.
And what you can see up there at the top
is that AHR is regulated by the CLOCK
because it shows a circadian rhythm in LD,
and then when you put them in DD,
they still see a nice circadian rhythm,
although it's not as robust.
And it's both in the SCN and the liver.
And CYP1A1, the target gene for AHR,
also shows a circadian rhythm.
So this is our first evidence
that AHR is regulated by the CLOCK.
So AHR is regulated downstream of the CLOCK.
And this is a study that was done by a group in Japan.
And they didn't do liver, they did lung.
And remember that I showed you on that one slide
that benzo-A-pyrene was a component of cigarette smoke.
And so there's lots of AHR in the lung,
and it's used to try to detoxify
some of these components of cigarette smoke
or other things that you would breathe in, okay?
So it makes sense that there would be this in the lung.
All right, so they looked at AHR messenger RNA in the lung,
and their animals were in LD,
and so we see it's the same thing,
a circadian rhythm, or a diurnal rhythm,
in AHR in the lung.
And then they looked at the target gene, CYP1A1,
and they see a nice rhythm of CYP1A1.
And one thing I wanna point out
is notice that the peak in the AHR occurs here around 17,
and the peak here occurs a little bit later, around 21,
which fits with the idea that this gene drives this gene.
So they looked at CYP1A1, the target gene,
they looked at CYP1A1 protein,
and they see a nice rhythm in the CYP1A1 protein.
They looked at CYP1A1 activity, it's an enzyme,
and they see that there's a rhythm in CYP1A1 activity.
So again, components of the arrow hydrocarbon signaling
pathway are regulated by the clock.
They also looked, in this same study,
they looked at binding of the arrow hydrocarbon receptor
to the dioxin response element.
So they took dioxin response element,
labeled it with something radioactive,
and then they put arrow hydrocarbon receptor
in there with it.
And what they can see is the binding to its target gene
is regulated by the clock.
So this band is higher than this one.
So there's more binding of arrow hydrocarbon receptor
at the time of day when the receptor was present more.
So we're getting increased,
we got increased messenger RNA and protein for AHR
and its target gene, and increased binding of AHR
to the gene elements to drive the activity of CYP1A1.
Then what they did to show, to really confirm
that this was regulated by the clock
was they took clock mutant mice.
And so the clock mutant mice
have a disrupted circadian timing system.
And so what they did here was they have wild type mice
and the clock mutant mice at two different times a day.
This is in the morning and this is at night.
And what we see is in the wild type mouse,
and this is arrow hydrocarbon receptor rest of RNA.
This is what they saw before,
higher levels of AHR at night, lower during the day.
But look what happens in the clock mutant mice.
So you take clock away, there's no clock anymore,
and AHR levels drop and there's no rhythm.
So the bottom line here is that arrow hydrocarbon receptor
is driven by the circadian clock
and the gene clock is probably very important
for its regulation.
So then in one more study that was done
by Kew et al. intoxilators in 2010.
This, they did the same thing.
In this case, they're looking at permute mice.
So they take mice that have altered per gene, right?
So here's the wild type animals here.
And now they're looking at, so we've shown,
the previous study was able to show
that AHR signaling is regulated by the clock.
But AHR, what does it do?
It binds to these toxins
and it stimulates toxin metabolism, okay?
So what they did in this study was they asked,
if we mess up the clock,
does it alter the ability of AHR
to respond to a toxin challenge?
So they give the animal a challenge to some sort of toxin
and they use TCDD, which is a really, really high,
is really toxic compound.
As they asked the question, in the permute mice,
do they have an altered ability to respond to the toxins?
So here's the wild type mice and we see that,
here's their response,
here's the control and response to TCDD
during the day and at night.
And you can see they have a much better ability
to respond to the toxic challenge at night.
But then when they take the,
when you look at the permute mice,
and let's just jump over here.
Here's the permute mice.
And this is, so this is the wild type.
So they have a small ability to respond
to the toxin during the day
and a much larger ability to respond to the toxin at night.
But if you take the permute mice,
their response to the toxin during the day
and during the night are the same.
So if you alter the circadian rhythm of the animal,
you decrease the production of AHR,
which we showed in the last slide,
and there's no more circadian rhythm in the ability
of the animal to respond to the toxin.
So to just summarize this, I just,
here's the bottom line.
AHR signaling is regulated by the clock.
So the AHR and the downstream components
are expressed in a circadian fashion,
and this occurs in many tissues.
I showed you a couple examples.
Clock mutant mice has decreased AHR expression
and no circadian rhythm,
and there's overall decrease in the expression of AHR
and no rhythm in AHR.
The permute mice lose their circadian rhythms
of their response to toxins.
So overall, the bottom line is, again,
my take home message,
AHR signaling is regulated by the clock.
Okay, now I'm gonna spend the next half hour,
the rest of the time, talking about the reverse.
So I'm gonna talk about how the dioxin signaling pathway
can, in reverse, feed back and interfere with the clock,
ring the clock.
So does, the question here is,
does AHR regulate the circadian clock?
And so we're gonna, I'm gonna show you
two different kinds of studies,
and all the studies that I'm gonna show you
are the ones that we've done in my lab.
So, and we use two different, two different methods here.
Studies, I'm gonna show you studies in knockout mice
where AHR is knocked out,
and I'm gonna study, show you studies
using AHR agonists or toxins.
So the first, the first question is,
in the first set of studies that I'm gonna show you,
I'm gonna ask the question,
if we remove AHR, does it matter?
Does their circadian rhythm care?
So do the AHR knockout mice have altered circadian rhythm?
And we're gonna, I'm gonna, have you seen these?
Behavioral, okay, so I don't have to explain these to you.
So, this is what we did.
We took wild-type mice,
and we took aryl hard-to-cover receptor knockout mice,
and we put them in, this is the,
at the top, they're in constant darkness,
so you see the wild-type mouse,
which, with the normal mouse circadian rhythm,
with getting a little bit shorter every day,
and then the ARCO mice.
Does anybody see any difference?
There might be just a little bit of a difference.
Yeah, there's not a lot of difference.
Maybe a little bit, not a difference.
So, when we first did this, we were kind of disappointed,
because we were like, oh, we really thought
that knocking out AHR was gonna really mess up
their circadian timing system.
But what we found was that their endogenous clock,
the endogenous rhythm, seems to be okay.
It doesn't have a lot of problems.
However, when we take the same AHR knockout mice,
and we do a phase-shift experiment,
where we alter the time with the lights on,
we've made it come on eight hours earlier,
and then we count the number of days it takes to re-entrain.
What we find is in the wild-type mice,
it takes around three and a half days, on average,
to re-entrain to the new light-dark cycle.
But the AHR knockout mice take about seven days to re-entrain.
To a phase advance, and they have no,
they're okay if you go the opposite way.
So, if you phase delay the lights on, they're okay.
So, what this tells us is that without the AHR,
the animals may have a little bit of a problem
responding to changes in the light-dark cycle,
or they get a little bit jet-lagged.
They have jet-lagged for a longer period of time.
So, if we fly these mice across the Atlantic,
they're gonna have a harder time
readjusting to the new time schedule.
That's the main point there.
All right, so it looks like they might have
an altered response to light.
So, what's the next experiment that we wanna do?
Anybody wanna take a guess?
We're gonna give them a shot of light at night,
and see if they respond normally.
So, in a wild-type mouse, if you give them a light pulse
in the early part of the night,
they're gonna get a delay, and they're circadian,
and it's gonna look like this.
If you give them a light pulse in the late part of the night,
they'll do a phase advance,
and they'll get something that looks like this.
So, we did the same experiment in the Arco mice,
and this is what we found.
In the Arco mice, we gave them a,
here's the wild-type with the phase delay,
and the Arco mouse actually has
a slightly bigger phase delay.
So, the animals do have an altered response to light.
This one might be exactly the opposite
of what we might have predicted from our other experiment,
because it took them longer to adjust
to the new time schedule,
but they actually have a slightly bigger response
to a phase delay in light,
and we're not sure exactly what that means.
At this point, all we know, really,
is that they have an altered ability to respond to light.
So then, they did show a little bit of a change
in their ability to respond to light,
so the next experiment we did was ask
if we give a toxin to the animal,
can it act like a light pulse?
So, will it activate the light signaling pathway?
And so, we did that experiment,
and we used two different,
we used tryptophan itself, which was in control,
we used this compound called FICZ.
Remember, this is that ligand
that has a high affinity for AHR,
and we see really no change.
So, the AHR ligands can't cause a light-like effect,
so we asked a different question,
and that was, if we give the animal a light pulse,
and we give the chemical at the same time,
does it block, or does it change,
the ability of the animal to respond to light?
So, if we activate the AHR,
does it change the animal's ability to respond to light?
So, we gave this drug, FICZ, the AHR ligand,
and then we gave the animal a light pulse,
and we can see that a normal animal
has about a little over a two-hour phase delay
in response to light.
In the presence of FICZ, it has a smaller phase delay,
so it does block the phase delay a little bit.
So, this is in a normal animal.
So, this is consistent with that previous data.
If we take AHR away, we have AHR knockout mice,
they have bigger phase delays in response to light.
So, AHR levels are down, they have bigger phase delays.
And here, when we activate AHR,
so we can think of AHR activity as high,
they have a lesser response to light.
So, the bottom line is that the AHR activation
can attenuate the light response,
and no AHR, the lack of an AHR,
makes a bigger light response.
And then we did the same experiment
using two different AHR agonists,
and that's just what this is showing.
This is a different AHR agonist,
and we see the same effect.
And this is a third different AHR agonist,
and we see the same effect.
And then we did it in the AHR knockout mice,
and we don't see the effect,
and we see the little bit bigger phase delay.
So, these are all consistent with the idea
that when there's no AHR,
we get a bigger response to light,
and when AHR is activated, we get a smaller response to light.
So, then we asked the question,
because when we gave these agonists,
we didn't inject them into the brain, we gave them IP.
So, AHR activation could be in the lever,
it could be anywhere.
So, we asked whether or not the AHR activation
was mediated directly by the suprachiasmatic nucleus.
We actually did this in Martha's lab.
You've probably seen this picture before.
Here's two little brain slices
sitting in a brain slice dish,
and we recorded the rhythm of their electrical activity.
And here, you'll see a normal rhythm
of electrical activity in the middle of the day.
If it phase delays, the peak in the activity occurs later,
and if it phase advances, it occurs earlier.
So, here's our experiment.
And in the dish, we've used glutamate
as a substitute for light,
and we can see that glutamate will cause a phase advance
when it's given in the late part of the night,
and a phase delay when it's given
in the early part of the night.
So, we've used this, and we gave glutamate,
or glutamate plus the AHR agonist.
And so, what we see is glutamate
causes normal phase advance, like we would expect.
When we give the AHR agonist, we get no change,
and when we put glutamate on with the AHR agonist,
we can block the phase advance.
So, this is just like what we saw in vivo, in the animal.
So, we were able to block the phase advance
of the behavior using an AHR agonist.
And here, in the dish, we were able to also block
the phase advance caused by glutamate.
In vivo, though, there was still a slight response, right?
So, we gave those, and that's a good question.
So, we gave those drugs, IV.
So, it could be a dose thing, and we don't know.
But they are lipid-soluble, so getting across
the blood-brain barrier shouldn't be a big issue.
But it could, and we haven't really done
a really good dose response with the drugs,
but it could be that, yeah.
Okay, so, and you may have seen this slide before,
because I stole it from Martha,
to our department, at least.
But here's light and glutamate signaling.
And when I was in Martha's lab,
we worked out, me, I worked on part of this,
and other people in the lab worked on part of this.
And we were able to show,
this is the signaling pathway for light.
But I wanna just focus on this right here.
So, when light hits the SCN,
it activates the signaling pathway, and per one goes up.
Okay, and this per one has to go up,
or the clock won't reset.
So, we decided to try to get at the molecular mechanism
by which AHR was interfering with the light response.
So, we asked the question, if we give light, or glutamate,
and the AHR agonist, what happens to per one?
That's what we asked.
So, normally it should go up.
If we block the light response,
we would expect that it won't go up, right?
So, we did that experiment.
And here is, we used light plus an AHR agonist called BNF.
So, here we see our control, here's BNF alone.
Here's light, and this is the SCN,
although the resolution's not real good.
But we see it goes up when you give light, this is per one,
and BNF blocks the effect.
So, the mechanism by which AHR agonists
can block the light and do phase advance,
or phase delay, is by blocking the induction of per one.
So, somewhere upstream of the induction of per one,
AHR is acting.
This is showing the same thing for a different agonist.
So, a lot of times in these toxicology studies,
they want you to show it with multiple agonists,
to show that you get the same effect.
So, here's the same thing,
looking at per one messenger RNA by qPCR.
We see that light makes per one go up,
and that is attenuated significantly.
Here, we're able to block it completely,
but it attenuates it significantly.
So, when we activate AHR, we block the light response,
and we block the induction of per one.
So, then we ask, so we know that the activation of the AHR,
the air hydrocarbon signaling pathway,
blocks the effects of light in the circadian timing system,
but what does it do to the normal rhythm?
That was the question.
Does it only have effects on the light signaling pathway,
or does it also affect the normal rhythm?
So, we looked at that, and so here's animals
where we treated animals with TCED,
and then we looked at the rhythm of per one,
in the SCN, and it has no effect.
There's no effect on the normal rhythm.
It only has an effect during the light response in the SCN.
However, now I wanna really focus on this interaction
between the SCN and the liver.
So, normally the SCN drives the rhythms
in the peripheral systems,
and one of the major places is it drives in the liver,
and the liver is really important for AHR,
because that's where we get the detoxification
of certain enzymes.
So, we asked this question.
Here's our previous experiment,
where we treated the animals with TCDD, the AHR agonist,
and we see no change in the SCN.
But look what happens in the liver.
We give TCDD, here's the normal rhythm
of per one in the liver, and after TCDD, we see a change.
So, basically, what we think is going on
is that activation of AHR has no real effect
on the main clock in the SCN,
but it obviously changes the clock in the liver.
So, if a person or an animal is exposed
to high levels of dioxin, what may be going on
is that the liver clock and the SCN clock
are no longer in sync with each other,
because the AHR agonists are messing up the liver clock,
but not affecting the clock in the SCN,
other than the light response,
but their endogenous clock is okay.
So, what we think may be happening
is that when the AHR agonists are there,
the clock in the liver is now not synchronized
any longer with the clock in the brain,
and that could cause all sorts of problems down the road.
We don't know what those problems are.
I'll give you a clue at the end,
but it could be causing problems.
So, it's causing desynchrony of the systemic timing system.
The one in the brain's okay,
but the clock in the liver's not okay anymore.
So, what's the mechanism by which AHR agonists
can alter this clock in the liver?
So, we looked into that, and we used a cell line.
This is a liver cell line,
and we have two different kinds of cells,
so it actually works like a knockout mouse,
because we've got this cell line
that expresses lots of IHR.
We've got another cell line that doesn't express it at all.
And so, what this shows is that
if we treat these cells,
either the C7 cells or the C12 cells,
with an AHR agonist, and we measure per,
this is per one levels,
we can see that the FICZ, the AHR agonist,
has a dose-dependent suppression of per one.
But in the cells that have no AHR,
when we get FICZ, it doesn't affect,
has no effect on per one levels.
And this is the same thing using a Western blot for per one.
So, we treat with an AHR agonist, one or the other,
and we see that in the cells that have high levels of AHR,
it suppresses per one protein, there and there.
But in the cells that have no AHR,
there's no suppression per one protein.
So, we believe that the mechanism,
just like what we saw for the light response,
the mechanism here for suppressing the clock
or messing up the clock in the liver
is by inhibiting per one.
We did this another way.
We used a luciferase reporter.
So, we took the per one promoter
and tagged it to a luciferase reporter.
And we did this experiment.
So, we took our cells,
and we expressed clock and BMAL in the cells.
And when you express clock and BMAL in the cells,
we see the per one luciferase levels go up
because they drive expression of per one.
And then what we did was we added AHR to the mix.
And just by adding the AHR, if we add enough of it,
you can see that it starts to come down.
And it's because this is kind of an artificial system,
so probably not all the AHR stays in the cytoplasm.
Some of it can leak into the nucleus
and activate transcription.
But look what happens when we express clock, BMAL, AHR,
and then add an AHR agonist.
We see that per one luciferase levels drop.
So, activation of AHR is able to suppress
the levels of per one in liver cells.
So, then what we did was we asked whether or not
this is occurring by binding to the per one promoter.
So, this is a CHIP assay.
Is everyone familiar with the CHIP assay?
Okay, so basically, what we're going to do here
is we have the per one promoter, right?
And we're going to look at, if we activate AHR,
do we get binding to the per one promoter?
Normally, we should get binding to the per one promoter.
So, this is our control.
This is the dioxin response element for CYP1A1,
the normal target gene, okay?
So, here we have AHR, a little binding of AHR
to the CYP1A1 promoter.
But look what happens when we add BNF, the agonist.
We increase the binding of AHR to the target gene promoter.
Okay, so that's our control.
So, then this is the E-box.
This is three of the five E-boxes in the per one promoter.
So, what we asked was, when we activate AHR with BNF,
do we see binding to the per one promoter?
And what we see here is, if we look here,
normally, we see CLOCK bounce to the E-box.
And look what happens when we add BNF.
When we add BNF, compare these two bands.
When we add BNF, we see, sorry, compare these two bands,
we see less binding of CLOCK to the E-box.
And we see an increased binding of AHR to the E-box.
So, what this tells us is two things.
When we activate AHR, it can actually bind
to the per one promoter.
And CLOCK binding to the per one promoter is decreased.
So, what we think is happening is it's coming in
and binding to BMOL1 and kicking CLOCK out.
So, CLOCK can't be there anymore.
And so, if there's no CLOCK in BMOL,
and so it's acting like a repressor.
So, if CLOCK binds to BMOL and they bind
to the per one promoter, we get increased per one.
What we think happens is when AHR comes in,
it kicks CLOCK out and binds to the per one promoter,
but it acts like a repressor.
So, it suppresses, it doesn't drive transcription
of per one, it suppresses it.
So, that's kind of what we think is going on.
And then, as I've shown you before,
this is just showing you that if we treat cells
with an AHR agonist and pull down with AHR,
then we can find BMOL1.
So, we know that AHR is capable of binding to BMOL1.
So, basically, what I showed you are a couple of things.
Mechanisms of per one induction,
and there are two ways that per one is regulated
by the circadian clock.
One is it's circadian regulation.
So, normally, we would see that there are e-boxes
in the per one promoter, and CLOCK and BMOL1
can bind to these e-boxes
and drive the transcription of per one.
Separate from that, when you give an animal a light pulse,
then CLOCK and BMOL1 will be pulled in
and binds to the per one promoter
and increase, acutely increase,
the transcription of per one.
That's sort of separate from this.
But there are two ways to regulate per one by the clock.
In addition, when you do light,
you also have to get CREB involved.
So, light, you activate CREB,
it helps CLOCK and BMOL1 to drive the transcription.
What we think is going on is that AHR activation
in the liver can actually block the ability
of CLOCK and BMOL1 to bind to the e-boxes here.
And so, it can suppress per one levels.
And we saw that in the liver.
We saw that with the circadian rhythm
because the rhythm, remember, the rhythm was delayed.
We saw that delay, and that's probably
because AHR is acting as a repressor
and not letting per one be made.
And then down here, when the light response occurs,
in the SCN, it may be preventing CLOCK and BMOL1
from binding to the e-box and preventing
the light induction of per one, which we saw.
So, yeah, so we think what's really going on,
as I alluded to before, was the AHR,
because it's so highly expressed in the liver,
when it's activated in the liver,
it alters the circadian rhythm in the liver,
and what it leads to is a desynchrony
between the CLOCK in the brain and the CLOCK in the liver,
and we believe that this can lead to pathology,
can lead to disease.
So, what kind of disease might we be talking about?
Well, there are a couple of, we know from epidemiological
studies that I've showed you that AHR activation
or exposure to dioxins can cause carcinogenesis,
it can cause all sorts of things.
I showed you in the beginning, and one of them was diabetes.
And so, what we've been working on lately in my lab
is asking the question, could the AHR alter
the circadian rhythm of glucose metabolism?
So, I will show you just a little bit of data from my lab.
This is wild-type mice and the
aryl hydrocarbon receptor knockout mice.
And this is blood glucose levels,
and so blood glucose levels measured
at four different times a day.
Now, we can see in the wild-type mice,
we see a nice circadian rhythm in serum blood glucose.
And then, look at the aryl hydrocarbon receptor
knockout mice.
So, they actually have better blood glucose levels,
but their circadian rhythm is suppressed.
So, if we look, then, at this gene,
peroxisome perflator actin, PPR-alpha.
If we look at that in the wild-type animals,
we see a nice circadian rhythm in PPR-alpha.
If we look at the aryl hydrocarbon receptor
knockout animals, we see that it's flat,
or that it's not significant.
So, basically, what this shows is that the
AHR knockout mice have altered circadian rhythms
in serum glucose and in PPR-alpha,
which is a gene that's important for glucose metabolism.
So, that's about as far as we've gotten.
So, what we are doing now is we're looking at,
well, actually, we have done one more study
that I didn't put here.
If you put animals on a high-fat diet,
they get diabetes.
They get high serum blood glucose and diabetes.
Okay, so, when, and we now know that
the aryl hydrocarbon receptor is involved.
And that's about as far as we've gotten.
So, to go any farther than that,
I'd probably be making things up.
But, all I want to say here is that AHR,
when you knockout AHR, you alter the circadian rhythm
in glucose metabolism, and you alter the expression
of genes that are important for glucose metabolism.
And we believe that this may be important,
an important mechanism that is a part
of how dioxins can cause diabetes.
So, that's where we'll just leave it there.
So, just to summarize the last part,
aryl hydrocarbon receptor knockout mice
have normal baseline circadian rhythms,
but they do have an altered light response.
When we activate the AHR using toxins or agonists for AHR,
we can attenuate the light effects in the SCN.
The activated AHR inhibits PER1.
AHR can do, and how does that happen?
Well, AHR can bind to BMAL1,
and it can replace CLOCK on the EBOX.
So, it displaces CLOCK.
So, CLOCK and BMAL can't bind to the receptor,
and can't drive the expression of PER1.
And then, finally, the aryl hydrocarbon receptor knockout
alters the circadian rhythms in liver metabolism,
especially glucose metabolism and serum-bulb glucose,
which may provide the link between circadian rhythms,
the aryl hydrocarbon receptor,
and the development of diabetes.
Because we know both circadian rhythms
and aryl hydrocarbon receptor,
or toxin exposure, can cause diabetes.
Altered circadian rhythms can cause diabetes,
and toxin exposure can cause diabetes.
And we believe that the aryl hydrocarbon receptor,
and its function is gonna be central
to linking the circadian rhythms to diabetes.
Is there other questions?
That's all I have.
Oh, that was the slide.
I'll just go through this on the last slide.
So, what we showed was that we get a big effect
of when you expose the animal to that dioxins.
We get a big effect on the CLOCK in the liver,
and a small effect on the CLOCK in the brain,
which may then, we believe, lead to a disruption.
So, we get an effect on the CLOCK in the liver,
very small effect on the CLOCK in the brain.
As I said before, we think that this disrupts the synchrony
between the CLOCK in the liver and the CLOCK in the brain.
And we think that once you've disrupted the synchrony,
it leads to pathology.
And in the case of liver metabolism,
the pathology that could be involved
is the altered glucose metabolism that leads to diabetes.
So, altered glucose metabolism,
we get metabolic syndrome and diabetes.
So, that's all I have.
So, I'm happy to take any questions, discussion, whatever.

